Beyond the standard 80 mg: Exposure-guided and equity-oriented precision dosing of Osimertinib in EGFR-mutant NSCLC
{{output}}
BackgroundOsimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has become foundational therapy across the EGFR-mutant non-small cell lung cancer (NSCLC) continuum, including first-line metastatic disease, unres... ...
